$INGN
Inogen Inc

2014 Form 10-K Financial Statement

#000156459015002861 Filed on April 27, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013 Q3
Revenue $112.5M $19.76M $19.78M
YoY Change 49.17% 43.2% 49.83%
Cost Of Revenue $57.02M $9.600M $6.751M
YoY Change 56.42% 41.18% 0.76%
Gross Profit $55.52M $10.18M $9.642M
YoY Change 42.38% 45.36% 48.34%
Gross Profit Margin 49.33% 51.49% 48.75%
Selling, General & Admin $42.03M $9.000M $8.082M
YoY Change 30.81% 42.86% 46.95%
% of Gross Profit 75.7% 88.45% 83.82%
Research & Development $2.977M $600.0K $700.0K
YoY Change 24.15% 20.0% 16.67%
% of Gross Profit 5.36% 5.9% 7.26%
Depreciation & Amortization $12.08M $2.540M $2.274M
YoY Change 41.39% 66.01% 83.39%
% of Gross Profit 21.76% 24.96% 23.58%
Operating Expenses $45.01M $9.600M $8.756M
YoY Change 30.35% 41.18% 45.93%
Operating Profit $10.51M $575.0K $886.0K
YoY Change 135.46% 187.5% 77.2%
Interest Expense $449.0K -$300.0K $113.0K
YoY Change -20.11% 200.0% -156.5%
% of Operating Profit 4.27% -52.17% 12.75%
Other Income/Expense, Net -$459.0K $0.00 -$69.00K
YoY Change -25.49%
Pretax Income $10.05M $200.0K $817.0K
YoY Change 161.23% 100.0% 308.5%
Income Tax $3.226M -$21.70M $43.00K
% Of Pretax Income 32.09% -10850.0% 5.26%
Net Earnings $6.826M $21.97M $774.0K
YoY Change -73.16% 21871.0% 287.0%
Net Earnings / Revenue 6.07% 111.18% 3.91%
Basic Earnings Per Share $0.33 $0.91 -$3.90
Diluted Earnings Per Share $0.30 $0.79 -$3.90
COMMON SHARES
Basic Shares Outstanding 16.18M 276.6K
Diluted Shares Outstanding 18.04M 276.6K

Balance Sheet

Concept 2014 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.80M $13.50M $17.10M
YoY Change 320.74% -10.6% 0.0%
Cash & Equivalents $56.80M $13.52M $13.52M
Short-Term Investments
Other Short-Term Assets $6.600M $4.700M $800.0K
YoY Change 40.43% 840.0% 33.33%
Inventory $7.600M $4.248M $4.100M
Prepaid Expenses
Receivables $19.30M $10.23M $9.700M
Other Receivables $2.200M $100.0K $0.00
Total Short-Term Assets $92.50M $32.80M $31.60M
YoY Change 182.01% 22.85% 12.46%
LONG-TERM ASSETS
Property, Plant & Equipment $31.90M $29.72M $28.60M
YoY Change 7.41% 46.41% 55.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.30M $1.765M $300.0K
YoY Change -21.94% 1665.0% 200.0%
Total Long-Term Assets $47.60M $1.765M $29.30M
YoY Change -4.03% -91.56% 53.4%
TOTAL ASSETS
Total Short-Term Assets $92.50M $32.80M $31.60M
Total Long-Term Assets $47.60M $1.765M $29.30M
Total Assets $140.1M $82.40M $60.90M
YoY Change 70.02% 73.1% 29.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.30M $8.800M $11.50M
YoY Change 28.41% 46.67% 43.75%
Accrued Expenses $4.100M $2.900M
YoY Change 41.38% 20.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $5.258M $5.400M
YoY Change -94.34% 34.82% 50.0%
Total Short-Term Liabilities $18.70M $18.83M $19.20M
YoY Change -0.53% 36.43% 50.0%
LONG-TERM LIABILITIES
Long-Term Debt $300.0K $5.391M $6.600M
YoY Change -94.44% 5.71% 8.2%
Other Long-Term Liabilities $2.900M $455.0K $800.0K
YoY Change 52.63% 127.5% 300.0%
Total Long-Term Liabilities $3.200M $5.846M $7.400M
YoY Change -56.16% 10.3% 17.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.70M $18.83M $19.20M
Total Long-Term Liabilities $3.200M $5.846M $7.400M
Total Liabilities $21.90M $26.10M $26.70M
YoY Change -16.09% 37.36% 40.53%
SHAREHOLDERS EQUITY
Retained Earnings -$62.62M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $118.2M -$62.37M $34.20M
YoY Change
Total Liabilities & Shareholders Equity $140.1M $82.40M $60.90M
YoY Change 70.02% 73.1% 29.03%

Cashflow Statement

Concept 2014 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income $6.826M $21.97M $774.0K
YoY Change -73.16% 21871.0% 287.0%
Depreciation, Depletion And Amortization $12.08M $2.540M $2.274M
YoY Change 41.39% 66.01% 83.39%
Cash From Operating Activities $15.70M $1.990M $4.600M
YoY Change 16.56% 8.74% -3166.67%
INVESTING ACTIVITIES
Capital Expenditures $1.551M -$490.0K -$1.220M
YoY Change -48.81% 16.67% 62.67%
Acquisitions
YoY Change
Other Investing Activities -$14.50M -$3.160M -$4.170M
YoY Change -3.85% 6.76% 47.87%
Cash From Investing Activities -$16.25M -$3.640M -$5.390M
YoY Change -10.42% 7.69% 51.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $213.0K
YoY Change 0.47%
Cash From Financing Activities 43.87M -1.890M 3.680M
YoY Change 1324.35% 329.55% -483.33%
NET CHANGE
Cash From Operating Activities 15.70M 1.990M 4.600M
Cash From Investing Activities -16.25M -3.640M -5.390M
Cash From Financing Activities 43.87M -1.890M 3.680M
Net Change In Cash 43.32M -3.540M 2.890M
YoY Change -2824.53% 77.89% -161.88%
FREE CASH FLOW
Cash From Operating Activities $15.70M $1.990M $4.600M
Capital Expenditures $1.551M -$490.0K -$1.220M
Free Cash Flow $14.15M $2.480M $5.820M
YoY Change 35.53% 10.22% 870.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1765000
CY2013Q4 us-gaap Assets
Assets
82397000
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19282247
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56836000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13521000
CY2014 us-gaap Revenues
Revenues
112537000
CY2014Q2 dei Entity Public Float
EntityPublicFloat
135071367
CY2013Q4 us-gaap Inventory Net
InventoryNet
4248000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10231000
CY2013Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
289000
CY2014Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
515000
CY2013Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
87000
CY2014Q4 ingn Construction In Process
ConstructionInProcess
193000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25840000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31927000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19349000
CY2014Q4 us-gaap Inventory Net
InventoryNet
7616000
CY2014Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
2129000
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2012 us-gaap Cost Of Revenue
CostOfRevenue
24627000
CY2012 us-gaap Revenues
Revenues
48576000
CY2013 us-gaap Cost Of Revenue
CostOfRevenue
36452000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-247000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
196000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2013 us-gaap Revenues
Revenues
75443000
CY2012 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17384000
CY2013 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24306000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
6826000
CY2014 us-gaap Cost Of Revenue
CostOfRevenue
57020000
CY2014 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
38693000
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 us-gaap Gross Profit
GrossProfit
23949000
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
15248000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97000
CY2014Q4 us-gaap Assets
Assets
140085000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
270000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
22159000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3637000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
267000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
60000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1564000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13628000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7462000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3570000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2150000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1705000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
543000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1168000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
230000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-21788000
CY2012 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12569000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8289000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2262000
CY2012 us-gaap Operating Expenses
OperatingExpenses
23120000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
829000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
230000
CY2012 ingn Health Care Organization Patient Service Revenue Adjustments
HealthCareOrganizationPatientServiceRevenueAdjustments
3102000
CY2013 us-gaap Inventory Write Down
InventoryWriteDown
78000
CY2012 us-gaap Inventory Write Down
InventoryWriteDown
42000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1451000
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
4976000
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
3923000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1122000
CY2014Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
48359000
CY2013Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
37573000
CY2014Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
3699000
CY2013Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
2973000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57767000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3745000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3390000
CY2014Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
141000
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2014Q4 ingn Rental Equipment Allowance
RentalEquipmentAllowance
832000
CY2013Q4 ingn Rental Equipment Allowance
RentalEquipmentAllowance
157000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
66666
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
66666
CY2014Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2013Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
250000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19059364
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
280974
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19059364
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
280974
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11273000
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8764000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4066000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2898000
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
299000
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5258000
CY2014Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
781000
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
420000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2316000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1487000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18735000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18827000
CY2014Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
334000
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
389000
CY2013Q4 ingn Preferred Stock Warrant Liability
PreferredStockWarrantLiability
260000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2176000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
776000
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
315000
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5391000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
375000
CY2013 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
12146000
CY2014 us-gaap Gross Profit
GrossProfit
55517000
CY2013 us-gaap Gross Profit
GrossProfit
38991000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2398000
CY2014 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
18327000
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0058
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
455000
CY2014Q4 us-gaap Liabilities
Liabilities
21935000
CY2013Q4 us-gaap Liabilities
Liabilities
26098000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
118671000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
247000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
174824000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56693000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62620000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
118150000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-62372000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140085000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82397000
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
73096000
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
44905000
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
28704000
CY2014 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
39441000
CY2013 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
30538000
CY2012 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
19872000
CY2012 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
7243000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2977000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24087000
CY2013 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18375000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17942000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13754000
CY2014 us-gaap Operating Expenses
OperatingExpenses
45006000
CY2013 us-gaap Operating Expenses
OperatingExpenses
34527000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
10511000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
4464000
CY2013 us-gaap Interest Expense
InterestExpense
562000
CY2012 us-gaap Interest Expense
InterestExpense
493000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
88000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-36000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
262000
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-148000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.68
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16182569
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
276535
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18037498
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2008156
CY2014 us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
10339000
CY2013 us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
7132000
CY2012 us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
4056000
CY2011Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
83122000
CY2012 ingn Warrants Converted To Temporary Equity Value
WarrantsConvertedToTemporaryEquityValue
442000
CY2012 us-gaap Temporary Equity Accretion Of Interest
TemporaryEquityAccretionOfInterest
55000
CY2012 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
5781000
CY2012Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
109345000
CY2013 ingn Warrants Converted To Temporary Equity Value
WarrantsConvertedToTemporaryEquityValue
2048000
CY2013 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
7278000
CY2014 ingn Warrants Converted To Temporary Equity Value
WarrantsConvertedToTemporaryEquityValue
593000
CY2014 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
987000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
120251000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-75566000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60000
CY2012 ingn Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
5000
CY2012 ingn Stock Issued During Period Accretion Of Financing Costs
StockIssuedDuringPeriodAccretionOfFinancingCosts
-55000
CY2012 ingn Deemed Dividend On Redeemable Convertible Preferred Stock
DeemedDividendOnRedeemableConvertiblePreferredStock
5781000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-80770000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2013 ingn Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
1000
CY2013 ingn Deemed Dividend On Redeemable Convertible Preferred Stock
DeemedDividendOnRedeemableConvertiblePreferredStock
7278000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1451000
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
413000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
946000
CY2014 ingn Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
61000
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
76000
CY2014 ingn Deemed Dividend On Redeemable Convertible Preferred Stock
DeemedDividendOnRedeemableConvertiblePreferredStock
987000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
49844000
CY2014 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
1641000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12080000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8544000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4984000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1895000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-305000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-258000
CY2014 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-2000
CY2013 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-16000
CY2012 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-5000
CY2014 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
3451000
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.97
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
261268
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
261268
CY2012 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
627000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1692000
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2045000
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1071000
CY2014 ingn Health Care Organization Patient Service Revenue Adjustments
HealthCareOrganizationPatientServiceRevenueAdjustments
7898000
CY2013 ingn Health Care Organization Patient Service Revenue Adjustments
HealthCareOrganizationPatientServiceRevenueAdjustments
6613000
CY2014 us-gaap Inventory Write Down
InventoryWriteDown
147000
CY2014 us-gaap Provision For Other Losses
ProvisionForOtherLosses
55000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1641000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2436000
CY2014 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
226000
CY2013 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
130000
CY2012 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
89000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
591000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
378000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
893000
CY2014 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
306000
CY2013 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
362000
CY2012 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
197000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2229000
CY2013 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
258000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1169000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
500000
CY2014 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
401000
CY2013 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
87000
CY2013 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-25000
CY2012 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
4000
CY2013 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
10000
CY2012 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3000
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-80000
CY2013 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
1770000
CY2012 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
139000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
15697000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
13467000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4004000
CY2014 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
205000
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
37000
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
63000
CY2014 ingn Payment To Produce Rental Equipment
PaymentToProduceRentalEquipment
14481000
CY2013 ingn Payment To Produce Rental Equipment
PaymentToProduceRentalEquipment
15075000
CY2012 ingn Payment To Produce Rental Equipment
PaymentToProduceRentalEquipment
10361000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1551000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3030000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2024000
CY2014 us-gaap Payments For Other Deposits
PaymentsForOtherDeposits
17000
CY2012 us-gaap Payments For Other Deposits
PaymentsForOtherDeposits
27000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16254000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18142000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12475000
CY2012 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
19945000
CY2014 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6000000
CY2013 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6000000
CY2012 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6000000
CY2014 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
506000
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
1883000
CY2012 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
422000
CY2014 ingn Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.0809
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
946000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
56471000
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6031000
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
597000
CY2014 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
413000
CY2014 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
213000
CY2013 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
212000
CY2012 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
213000
CY2014 us-gaap Repayments Of Debt
RepaymentsOfDebt
15861000
CY2013 us-gaap Repayments Of Debt
RepaymentsOfDebt
4000000
CY2012 us-gaap Repayments Of Debt
RepaymentsOfDebt
6480000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1641000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
43872000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3084000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19677000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
43315000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1591000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11206000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15112000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3906000
CY2014 us-gaap Interest Paid
InterestPaid
487000
CY2013 us-gaap Interest Paid
InterestPaid
552000
CY2012 us-gaap Interest Paid
InterestPaid
462000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
2061000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
311000
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
37000
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which we call the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company&#8217;s proprietary Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or 7.0 pounds. Our Inogen One G3 and G2 have up to 4.5 and 5 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Companies Inogen One systems reduce the patient&#8217;s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates used in preparing these financial statements include accounts receivable reserves, inventory reserves, warranty reserves, warrant liability, stock-based compensation expense and income tax provision. Actual results could differ from those estimates and such differences could be material to the financial position and results of operations. </p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents and short-term investments to date. </p></div>
CY2014 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to prior year financial statements to conform to current period financial statement presentation. These revisions increased working capital by $844 at December 31, 2013, but did not impact previously reported total revenue, net income, earnings per share, stockholders&#8217; deficit or cash flows. </p></div>
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
169000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
15000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
211000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
15000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
798000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-523000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
313000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-88000
CY2012 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-611000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-614000
CY2012 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
3000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
3575000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2686000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
42000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
525000
CY2013 us-gaap Shipping And Handling Revenue
ShippingAndHandlingRevenue
376000
CY2014 us-gaap Extended Product Warranty Description
ExtendedProductWarrantyDescription
The second deliverable is the lifetime warranty that provides for a functional oxygen concentrator for the remaining lifetime of the patient
CY2014 ingn Number Of Products Qualify As Separate Units
NumberOfProductsQualifyAsSeparateUnits
2
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1367000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5217000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
546142
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15937343
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
128016
CY2013 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
219766
CY2014 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
The first deliverable is the oxygen concentrator equipment which comes with a standard warranty of three years
CY2014 us-gaap Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Method
RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceMethod
the company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, the company estimates on average all patients will succumb to their disease within five years.
CY2014 us-gaap Shipping And Handling Revenue
ShippingAndHandlingRevenue
486000
CY2012 us-gaap Shipping And Handling Revenue
ShippingAndHandlingRevenue
214000
CY2014Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1115000
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
809000
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1726913
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1511855
CY2012 us-gaap Depreciation
Depreciation
4686000
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Advertising Expense
AdvertisingExpense
3290000
CY2013 us-gaap Advertising Expense
AdvertisingExpense
2840000
CY2012 us-gaap Advertising Expense
AdvertisingExpense
2503000
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
3:1
CY2014 ingn Effective Date Of Reverse Stock Split
EffectiveDateOfReverseStockSplit
2013-11-12
CY2013 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
844000
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4411763
CY2014 us-gaap Revenue Recognition New Accounting Pronouncement Timing
RevenueRecognitionNewAccountingPronouncementTiming
30-day period
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
260000
CY2012Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
164000
CY2013 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
-166000
CY2013 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
-262000
CY2013Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
260000
CY2014 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
-148000
CY2014 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
36000
CY2014 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
76000
CY2014Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
3653000
CY2013Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1435000
CY2013 ingn Number Of Customers
NumberOfCustomers
0
CY2014 ingn Number Of Customers
NumberOfCustomers
0
CY2014Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
6774000
CY2013Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
3783000
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
983000
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
565000
CY2014 us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
0
CY2014Q4 us-gaap Property Plant And Equipment Salvage Value
PropertyPlantAndEquipmentSalvageValue
1628000
CY2013Q4 us-gaap Property Plant And Equipment Salvage Value
PropertyPlantAndEquipmentSalvageValue
1020000
CY2014 us-gaap Depreciation
Depreciation
11930000
CY2013 us-gaap Depreciation
Depreciation
8341000
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
16.00
CY2014Q1 ingn Common Stock Purchased By Underwriters
CommonStockPurchasedByUnderwriters
99550
CY2014Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
14259647
CY2014 ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
5839000
CY2013 ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
18157000
CY2012 ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
-5217000
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
7165000
CY2014 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
567000
CY2013 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
10781000
CY2014 ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
5272000
CY2013 ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
211000
CY2012 ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
-5217000
CY2014 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
514000
CY2013 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
9625000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5325000
CY2014 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P2Y
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
150000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
203000
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
298000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1186000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
916000
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
981000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
766000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
84000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
65000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
48000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
48000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
25000
CY2012Q4 us-gaap Line Of Credit Facility Commitment Fee Percentage
LineOfCreditFacilityCommitmentFeePercentage
0.01
CY2012Q4 us-gaap Line Of Credit Facility Commitment Fee Amount
LineOfCreditFacilityCommitmentFeeAmount
120000
CY2014Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
12000000
CY2014Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
15000000
CY2014Q4 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0125
CY2014Q4 ingn Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
10000000
CY2014Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2014Q3 ingn Outstanding Term Loan And Accrued Interest Paid
OutstandingTermLoanAndAccruedInterestPaid
11600000
CY2014Q4 us-gaap Long Term Debt
LongTermDebt
614000
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
10649000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
299000
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
315000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1139000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1664000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2782000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
3000
CY2014 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
2785000
CY2013 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1111000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1223000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22909000
CY2014 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
1562000
CY2013 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-21798000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22924000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25233000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2899000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4122000
CY2014Q4 ingn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance Reserves And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceReservesAndOther
1965000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
25565000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
23797000
CY2014Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3674000
CY2013Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1643000
CY2014Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1667000
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
366000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
5341000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2009000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
20224000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
21788000
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0247
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0548
CY2014Q2 us-gaap Gross Profit
GrossProfit
15114000
CY2014Q2 us-gaap Revenues
Revenues
30393000
CY2014Q1 us-gaap Gross Profit
GrossProfit
11938000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
1519000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0453
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1216
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-5.9534
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0349
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0139
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0254
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0277
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
-0.0025
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0204
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
-0.0825
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
-1.3726
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.0555
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
457000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
477000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0102
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3209
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-5.6099
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0303
CY2014 ingn Change In Ownership Description
ChangeInOwnershipDescription
In general, an “ownership change” occurs if there is a cumulative change in ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period.
CY2014Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.05
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
577000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
306000
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
123000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
148000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
306000
CY2014 us-gaap Significant Change In Unrecognized Tax Benefits Nature Of Event
SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent
We do not expect a material increase or decrease in unrecognized tax benefits over the next 12 months.
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
870000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
483000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
458000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
313000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3058000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
750000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
910000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
806000
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
447000
CY2014 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1075000
CY2013 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
533000
CY2014 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
406000
CY2013 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
322000
CY2014 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1175000
CY2013 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
493000
CY2014 ingn Voting Rights Associated With Each Share Of Common Stock
VotingRightsAssociatedWithEachShareOfCommonStock
1
CY2013 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0
CY2012 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
0
CY2014 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Prior to our IPO, each share of preferred stock was automatically convertible into common stock, at the then applicable conversion rate, upon (i) the election of both the holders of a majority of the then-outstanding Series F preferred stock and Series G preferred stock, voting together as a single class provided, or (ii) the closing of an underwritten initial public offering of the Company’s common stock pursuant to a registration statement under the Securities Act of 1933, as amended with aggregate proceeds of at least $40 million at an offering price of at least $17.85 per share (as adjusted for stock splits, stock dividends, recapitalizations, etc.). If the Series G preferred shares were converted to common stock in connection with an initial public offering in which shares are sold to the public at a price that was less than $14.0832 per share (as adjusted for stock splits, stock dividends, recapitalizations, etc.), then immediately prior to such conversion, the applicable conversion rate of the Series G preferred stock was to be increased to the extent necessary to make the Series G preferred holders whole as if the initial public offering price to the public had been equal to $14.0832 (as adjusted for stock splits, stock dividends, recapitalizations, etc.).
CY2014 us-gaap Temporary Equity Contract Terms
TemporaryEquityContractTerms
Prior to our IPO, the holders of at least 66 2/3% of preferred stock on an as converted to common stock basis were required to approve certain specified actions as outlined in the Company’s prior Certificate of Incorporation. In addition, the holders of at least 60% of the Series D preferred stock were required to approve certain specified actions as outlined in the Company’s prior Certificate of Incorporation. In addition, the Company could not amend its prior Certificate of Incorporation without the approval of at least 66 2/3% of any series of preferred stock if such amendment would change any of the rights, preferences or privileges of such series.
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1646223
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
716326
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8874
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
23106
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1894
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2328675
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1524325
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2226738
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M27D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
80640
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y15D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
754916
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
736519
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4799
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.81
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.09
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.31
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.02
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.19
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2261633
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1100539
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2144974
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.06
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.95
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.35
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.46
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.53
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.94
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
1.16
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.88
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.81
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.28
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y11M12D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M5D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y8M23D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M17D
CY2012 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare
0.41
CY2013 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare
10.23
CY2013Q4 ingn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue
11.01
CY2013Q4 ingn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue
10.29
CY2014 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare
24.06
CY2014Q4 ingn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue
29.35
CY2014Q4 ingn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue
24.18
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15495000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
30000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2261633
CY2014 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y5M5D
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.31
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1100539
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.02
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2328675
CY2013 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y15D
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
1.94
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1524325
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
1.16
CY2014 ingn Share Based Compensation Expense Reduced Rate For Estimated Forfeiture
ShareBasedCompensationExpenseReducedRateForEstimatedForfeiture
0.069
CY2013 ingn Share Based Compensation Expense Reduced Rate For Estimated Forfeiture
ShareBasedCompensationExpenseReducedRateForEstimatedForfeiture
0.070
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0132
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0108
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0073
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0202
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0176
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0133
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.4215
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.501
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.4895
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
2286000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5273
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5277
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5052
CY2014 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue
5329000
CY2013 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue
1705000
CY2012 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue
95000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4948000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1370000
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
263463
CY2014 ingn Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
245489
CY2014 ingn Class Of Warrant Or Right Number Of Warrants Or Rights Expired
ClassOfWarrantOrRightNumberOfWarrantsOrRightsExpired
2756
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15218
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
384217
CY2013 ingn Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
85895
CY2013 ingn Class Of Warrant Or Right Number Of Warrants Or Rights Expired
ClassOfWarrantOrRightNumberOfWarrantsOrRightsExpired
34859
CY2014Q4 ingn Preferred Stock Warrant Liability
PreferredStockWarrantLiability
0
CY2014Q1 us-gaap Revenues
Revenues
23633000
CY2014Q3 us-gaap Revenues
Revenues
29393000
CY2014Q4 us-gaap Revenues
Revenues
29118000
CY2014Q3 us-gaap Gross Profit
GrossProfit
14649000
CY2014Q4 us-gaap Gross Profit
GrossProfit
13816000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
888000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
2133000
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2013Q1 us-gaap Revenues
Revenues
15747000
CY2013Q2 us-gaap Revenues
Revenues
20157000
CY2013Q3 us-gaap Revenues
Revenues
19777000
CY2013Q4 us-gaap Revenues
Revenues
19762000
CY2013Q1 us-gaap Gross Profit
GrossProfit
8117000
CY2013Q2 us-gaap Gross Profit
GrossProfit
11057000
CY2013Q3 us-gaap Gross Profit
GrossProfit
9642000
CY2013Q4 us-gaap Gross Profit
GrossProfit
10175000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
730000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
1960000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
774000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
21971000
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.65
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.90
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.91
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.65
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.90
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79

Files In Submission

Name View Source Status
0001564590-15-002861-index-headers.html Edgar Link pending
0001564590-15-002861-index.html Edgar Link pending
0001564590-15-002861.txt Edgar Link pending
0001564590-15-002861-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201504261750574761086.jpg Edgar Link pending
g20150426175059087466.jpg Edgar Link pending
g20150426175059564937.jpg Edgar Link pending
g20150426175107763845.jpg Edgar Link pending
g20150426175107810846.jpg Edgar Link pending
g20150426175109513847.jpg Edgar Link pending
g20150426175123529848.jpg Edgar Link pending
g20150426175129165467.jpg Edgar Link pending
g20150426175131420849.jpg Edgar Link pending
g20150426175140525468.jpg Edgar Link pending
ingn-10k_20141231.htm Edgar Link pending
ingn-20141231.xml Edgar Link completed
ingn-20141231.xsd Edgar Link pending
ingn-20141231_cal.xml Edgar Link unprocessable
ingn-20141231_def.xml Edgar Link unprocessable
ingn-20141231_lab.xml Edgar Link unprocessable
ingn-20141231_pre.xml Edgar Link unprocessable
ingn-ex1023_20141231157.htm Edgar Link pending
ingn-ex1024_2014123184.htm Edgar Link pending
ingn-ex1025_2014123183.htm Edgar Link pending
ingn-ex1026_2014123182.htm Edgar Link pending
ingn-ex231_201412311292.htm Edgar Link pending
ingn-ex311_20141231452.htm Edgar Link pending
ingn-ex312_20141231453.htm Edgar Link pending
ingn-ex321_20141231454.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending